GSK, a pharmaceutical and biotechnology company, completed the acquisition of Elsie Biotechnologies, a biopharmaceutical company, for $50m. "We are thrilled to be a part of GSK and work alongside the talented R&D team dedicated to oligonucleotide drug development. We believe our platform will make significant contributions to the field and we believe GSK is the best partner to help advance this effort," Kevin Green, Elsie COO.